Fresenius Kabi and Bayer Schering Pharma enter into a Research, Development and License Agreement

04-Jun-2009 - Germany

Fresenius Kabi Deutschland GmbH and Bayer Schering Pharma AG have signed a Research, Development and License Agreement regarding the use of Fresenius Kabi Deutschland GmbH’s HESylation® Technology in a limited field of use.

Under the agreement, Fresenius Kabi will license its proprietary HESylation® Technology to Bayer Schering Pharma. This technology platform is based on hydroxyethyl starch (“HES”) and allows the prolongation of the active half-life of proteins.

Fresenius Kabi will be responsible for providing the appropriate HES derivative to Bayer Schering Pharma. Under the agreement, Bayer Schering Pharma will oversee the development and commercialisation. Fresenius Kabi will receive up-front and milestone payments as well as royalties on sales for licensing of the HESylation® Technology.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance